Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Cited In for PubMed (Select 11896095)

1.

Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience.

Asleh-Aburaya K, Fried G.

Springerplus. 2015 Mar 15;4:132. doi: 10.1186/s40064-015-0900-3. eCollection 2015.

2.

Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.

Ahlborn LB, Dandanell M, Steffensen AY, Jønson L, Nielsen FC, Hansen TV.

Breast Cancer Res Treat. 2015 Apr;150(2):289-98. doi: 10.1007/s10549-015-3313-7. Epub 2015 Feb 28.

3.

Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?

Cheon JY, Mozersky J, Cook-Deegan R.

Genome Med. 2014 Dec 19;6(12):121. doi: 10.1186/s13073-014-0121-3. eCollection 2014.

4.

Breast cancer genetic testing awareness, attitudes and intentions of Latinas living along the US-Mexico border: a qualitative study.

Chalela P, Pagán JA, Su D, Muñoz E, Ramirez AG.

J Community Med Health Educ. 2012;2. pii: 1000152.

5.

Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons.

Acedo A, Hernández-Moro C, Curiel-García Á, Díez-Gómez B, Velasco EA.

Hum Mutat. 2015 Feb;36(2):210-21. doi: 10.1002/humu.22725.

6.

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

7.

Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.

van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK.

Eur J Hum Genet. 2015 May;23(5):588-95. doi: 10.1038/ejhg.2014.161. Epub 2014 Aug 20.

PMID:
25138101
8.

BRCA-associated ovarian cancer: from molecular genetics to risk management.

Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D.

Biomed Res Int. 2014;2014:787143. doi: 10.1155/2014/787143. Epub 2014 Jul 22.

9.

BRCA genetic counseling among at-risk Latinas in New York City: new beliefs shape new generation.

Sussner KM, Edwards T, Villagra C, Rodriguez MC, Thompson HS, Jandorf L, Valdimarsdottir HB.

J Genet Couns. 2015 Feb;24(1):134-48. doi: 10.1007/s10897-014-9746-z. Epub 2014 Aug 15.

10.

Understanding patient and provider perceptions and expectations of genomic medicine.

Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB.

J Surg Oncol. 2015 Jan;111(1):9-17. doi: 10.1002/jso.23712. Epub 2014 Jul 3. Review.

PMID:
24992205
11.

Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study.

Sharma S, Rajaram S, Sharma T, Goel N, Agarwal S, Banerjee BD.

Int J Biochem Mol Biol. 2014 May 15;5(1):1-10. eCollection 2014.

12.

BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development.

Feilotter HE, Michel C, Uy P, Bathurst L, Davey S.

PLoS One. 2014 Jun 20;9(6):e100068. doi: 10.1371/journal.pone.0100068. eCollection 2014.

13.

Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1.

Carvalho RS, Abreu RB, Velkova A, Marsillac S, Rodarte RS, Suarez-Kurtz G, Iversen ES, Monteiro AN, Carvalho MA.

PLoS One. 2014 May 20;9(5):e97766. doi: 10.1371/journal.pone.0097766. eCollection 2014.

14.

The role of testing for BRCA1 and BRCA2 mutations in cancer prevention.

McCarthy AM, Armstrong K.

JAMA Intern Med. 2014 Jul;174(7):1023-4. doi: 10.1001/jamainternmed.2014.1322. No abstract available.

15.

Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.

Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK.

Ann Surg Oncol. 2014 Oct;21(11):3466-72. doi: 10.1245/s10434-014-3747-x. Epub 2014 May 6.

PMID:
24796968
16.

Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy.

Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ.

Mayo Clin Proc. 2014 Jun;89(6):727-37. doi: 10.1016/j.mayocp.2014.01.025. Epub 2014 May 1.

PMID:
24793961
17.

[Breast cancer in men: about 6 cases].

Laabadi K, Jayi S, Alaoui FF, Bouguern H, Chaara H, Melhouf MA, Hassani KI, Laalim SA, Anoun H, Toughrai I, Mazaz K.

Pan Afr Med J. 2013 Oct 28;16:70. doi: 10.11604/pamj.2013.16.70.2345. eCollection 2013. French. No abstract available.

18.

The BRCA1 variant p.Ser36Tyr abrogates BRCA1 protein function and potentially confers a moderate risk of breast cancer.

Christou CM, Hadjisavvas A, Kyratzi M, Flouri C, Neophytou I, Anastasiadou V, Loizidou MA, Kyriacou K.

PLoS One. 2014 Apr 2;9(4):e93400. doi: 10.1371/journal.pone.0093400. eCollection 2014.

19.

Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.

Kim H, Choi DH.

J Breast Cancer. 2013 Dec;16(4):357-65. doi: 10.4048/jbc.2013.16.4.357. Epub 2013 Dec 31. Review.

20.

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

Senkus E, Szade J, Pieczyńska B, Zaczek A, Pikiel J, Sosińska-Mielcarek K, Karpińska A, Jassem J.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):353-63. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk